Effect of Songyu Anshen Fang on expression of hypothalamic GABA and GABA(B) receptor proteins in insomniac rats induced by para-chlorophenylalanine
Purpose: To investigate the effects of the Chinese compound, Songyu Anshen Fang (SYF) on levels of GABA and GABA(B) receptor proteins in insomniac rats induced by para-chlorophenylalanine (PCPA).
Methods: All rats were randomly separated into either a control group, insomnia group, or a SYF group (at a dose of 8.5 g/kg or 17 g/kg body weight per day). The rat model of insomnia was induced by intraperitoneal injection of PCPA, and SYF was administered intragastrically in suspension. All experimental groups were treated with a corresponding agent for one week. The levels of glutamic acid (Glu) and γ-aminobutyric acid (GABA) were determined by high performance liquid chromatography (HPLC); mRNA and protein expressions, and GABA(B) receptor levels were detected by real-time polymerase chain reaction (RT-PCR) and western blot.
Results: SYF treatment with 8.5 or 17 g/kg/day decreased the levels of Glu and Glu/GABA ratios in the hypothalamus following abnormal increase by PCPA. Moreover, GABA(B) receptor, mRNA and protein expression decreased by PCPA in hypothalamus were significantly normalized by SYF.
Conclusion: The study indicates that the effects of PCPA-induced insomnia can be alleviated by SYF modulation of neurotransmitter levels and the expression of GABA(B) receptor in the hypothalamus. This suggests that clinical application of SYF to treat insomnia may be feasible.
Keywords: Songyu Anshen Fang, Para-chlorophenylalanine (PCPA), γ-Aminobutyric acid (GABA), GABA(B) receptor, Insomnia
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.